NHS BLOOD AND TRANSPLANT
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.nhsbt.nhs.uk
NHS England Approves Gene-Editing Therapy Casgevy for Severe Sickle Cell Disease
• NHS England approves Casgevy, a gene-editing therapy, for treating severe sickle cell disease in eligible patients aged 12 and over.
• Casgevy, also known as exa-cel, modifies a patient's stem cells to produce healthy red blood cells, potentially curing the disease.
• Clinical trials showed that Casgevy significantly reduced hospitalizations, offering a 'functional cure' for nearly all participants.
• The treatment will be available at specialist NHS centers, providing hope for improved quality of life for sickle cell patients.
The TREATT Trial: Evaluating Tranexamic Acid in Haematological Malignancies
The TREATT trial investigates the use of tranexamic acid (TXA) in patients with haematological malignancies to reduce bleeding and the need for platelet transfusions. This multinational, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of TXA during periods of severe thrombocytopenia.
© Copyright 2025. All Rights Reserved by MedPath